Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) generates a steady flow of news as a clinical-stage oncology company advancing RNA-targeted therapeutics for cancer. This news page aggregates press releases and third-party coverage related to TransCode’s development programs, corporate actions, and scientific collaborations, giving readers a centralized view of how the company’s RNA oncology strategy is progressing.
Much of the company’s news focuses on its lead candidate, TTX-MC138, an RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which TransCode identifies as a key factor in metastatic cancer. Updates include milestones from its Phase 0 and Phase 1a clinical trials in metastatic solid tumors, reports on safety and pharmacodynamic data, and announcements about advancing TTX-MC138 into Phase 2a studies across selected metastatic indications and minimal residual disease settings.
Readers can also follow news about preclinical research using the TTX platform, such as studies in glioblastoma models demonstrating delivery of TTX-MC138 to brain tumors, target engagement, and extended survival in murine models. These items highlight how TransCode’s nanoparticle platform is being evaluated for systemic delivery of RNA therapeutics to challenging tumor sites.
Beyond clinical and preclinical data, TransCode’s news includes corporate and strategic developments, such as the acquisition of Polynoma and the addition of seviprotimut-L, a polyvalent shed antigen vaccine for stage IIB and IIC melanoma, to its pipeline. Filings and releases also cover financing transactions with affiliates of CK Life Sciences, reverse stock split decisions related to Nasdaq listing requirements, and governance updates including board and executive appointments.
For investors, researchers, and clinicians, following RNAZ news offers insight into TransCode’s progress in metastatic disease, its expanding immuno-oncology and RNA pipeline, and the regulatory and capital markets events that shape its development path. Bookmark this page to review new trial readouts, platform data, and transaction announcements as they are released.
TransCode Therapeutics (NASDAQ: RNAZ) announced publication of a peer-reviewed preclinical manuscript, Template-Directed RIG-I Agonist Assembly, published February 19, 2026 in Molecular Imaging and Biology.
The study reports a tumor-selective RIG-I agonist approach that uses overexpressed oncogenic microRNAs (eg, miRNA-21) as intracellular assembly templates and highlights image-guided delivery using TransCode's TTX nanoparticle platform, which is currently in clinical trials.
TransCode (NASDAQ: RNAZ) and Quantum Leap submitted an IND amendment to the FDA for a planned Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer (NCT05868226).
The PRE-I-SPY platform trial will enroll up to 45 ctDNA-positive patients post‑curative therapy, aims to start in H1 2026, and will be led by Dr. Paula Pohlmann.
TransCode Therapeutics (NASDAQ: RNAZ) reported preclinical data showing its lead candidate TTX-MC138 reaches orthotopic glioblastoma tumors after intravenous dosing and produces sustained target engagement against miR-10b.
The study in murine models reported a 5-fold increase in apoptotic activity in tumors and a statistically significant survival benefit. IND‑enabling studies, PK/biodistribution, and toxicity work have been completed, and Phase 1 safety data exist in non-CNS patients; a Phase 2a trial is anticipated in H1 2026.
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors effective Dec. 22, 2025.
Mr. Stover will join the Audit and Nominating Committees while Dr. Magda Marquet steps down from the Audit Committee. He brings over three decades of executive experience across drug development, diagnostics, specialty pharmaceuticals, and capital formation and has led mergers, financings, and company sales.
Notable roles cited include chairman of Traws Pharma, director and audit chair at Onconova, CEO of NorthView Acquisition Corp from March 2021 to July 2025, director of Profusa, and prior CEO roles at Interpace Biosciences and Antares Pharma (sale of Antares to Halozyme for in excess of $900 million).
TransCode Therapeutics (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative announced a collaboration to evaluate TTX-MC138 in the Quantum Leap PRE-I-SPY Phase 2a dose-expansion trial for colorectal cancer.
The Phase 2a will enroll up to 45 patients with ctDNA-positive minimal residual disease who completed curative-intent therapy, is planned to begin in H1 2026, and will be led by Dr. Paula Pohlmann at MD Anderson. The move follows TransCode's Phase 1a observation of an encouraging safety profile and durable anti-tumor effects, which the companies say support further efficacy testing in the MRD setting where recurrence risk is high.
TransCode Therapeutics (NASDAQ: RNAZ) on November 17, 2025 appointed Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer, initially part-time. Dr. Janicot brings >35 years in pharmaceutical research and early clinical development with expertise in RNA biology, translational medicine, and oncology strategy. He will support strategic R&D and clinical development for lead programs TTX-MC138 and Seviprotimut-L as they advance toward late-stage trials.
Dr. Janicot founded JMi ONConsulting, has led programs at Janssen, and authored >360 scientific works.
TransCode Therapeutics (NASDAQ: RNAZ) reported completion of its Phase 1a trial of TTX-MC138, an investigational miR-10b inhibitor, and met the trial's primary safety endpoint. Sixteen patients were treated across four dose levels with no dose-limiting toxicities observed and a recommended Phase 2 dose established. Median treatment duration was 4 months (range 2–12 months); three patients remain on study. Forty-four percent (7/16) had stable disease ≥4 months. Positive pharmacodynamic effects were seen across the dose range. Data are preliminary; a poster presentation is scheduled for ESMO, Oct 17–21, 2025, and a Phase 2a trial is planned.
TransCode Therapeutics (NASDAQ: RNAZ) announced on October 8, 2025 the acquisition of 100% of Polynoma and a concurrent $25 million equity investment from CK Life Sciences. The deal adds Polynoma’s Phase 3–ready seviprotimut-L (a polyvalent shed‑antigen vaccine for adjuvant treatment of stage IIB/IIC melanoma) to TransCode’s microRNA pipeline.
Proceeds will primarily advance TransCode’s lead microRNA asset, TTX‑MC138, into a Phase 2 trial. Philippe Calais becomes CEO and remains board chair; Tom Fitzgerald returns to CFO; Elizabeth Czerepak joins as independent board member and audit chair. The company expects to retain Polynoma development, finance, and manufacturing staff.
TransCode Therapeutics (NASDAQ: RNAZ) has announced successful completion of initial dosing in Cohort 4 of its Phase 1a clinical trial for TTX-MC138. Key highlights include:
- 15 patients treated across 4 dose levels (0.8 mg/kg to 4.8 mg/kg)
- No significant safety or dose-limiting toxicities reported
- 10 patients remain on study with stable disease
- Two patients received 7 doses over ~7 months showing stable disease
- PK/PD data shows predictable dose-response relationship
- Evidence of miR-10b target engagement at 24 hours post-infusion in Cohorts 1 and 2
- Safety Review Committee approved expanded enrollment in Cohort 3
The positive results support advancement to the Phase 1b dose expansion portion of the trial.